IP Library › Granted Patent US 12,416,015
Granted Patent B2
US 12,416,015 · App. 16/646,999 · Granted Sep 16, 2025

Multiplex production and barcoding of genetically engineered cells

Inventors: Kevin Roy (Mountain View, CA); Justin D. Smith (Redwood City, CA); Robert P. St. Onge (San Francisco, CA); Lars M. Steinmetz (Stanford, CA); James E. Haber (Waltham, MA)
Assignees: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY; BRANDEIS UNIVERSITY
C12N15/85C12N9/22C12N15/1082C12N15/113C12N15/81C12N2310/20C12N2800/80
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,416,015
App. No.
16/646,999
Granted
Sep 16, 2025
Kind
B2
Abstract

The present disclosure relates to multiplex production and phenotyping of genetically engineered cells using RNA-guided nucleases and genomic barcoding. In particular, high-throughput multiplex genome editing is achieved utilizing a system that facilitates precise genome editing at desired target chromosomal loci by homology directed repair. Integration of guide RNA and donor DNA sequences as a genomic barcode at a separate chromosomal locus allows identification, isolation, and massively-parallel validation of individual variants from a pool of transformants. Strains can be arrayed according to their precise genetic modifications, as specified by donor DNA incorporation in heterologous or native genes. The present disclosure further relates to a method of editing codons outside of canonical guide RNA recognition regions, which enables complete saturation mutagenesis of protein-coding genes, a marker-based internal cloning method, which removes background due to oligonucleotide synthesis errors and incomplete vector backbone cleavage, and a method of enhancing homology directed repair by active donor recruitment.

Claims (45)

1. A method for localizing a donor polynucleotide to a genomic target locus in a target cell, the method comprising:

(a) transfecting a target cell with a first recombinant polynucleotide, the first recombinant polynucleotide comprising a genome editing cassette comprising:

(i) a promoter operably linked to a nucleic acid sequence encoding a guide RNA (gRNA) capable of hybridizing at a genomic target locus to be modified, and

(ii) a donor polynucleotide comprising a sequence to be integrated into the genomic target locus;

(b) transfecting the target cell with a second recombinant polynucleotide that encodes a first polypeptide and encodes a second polypeptide, wherein:

(i) the first polypeptide is an RNA-guided nuclease, wherein the RNA-guided nuclease when complexed with the gRNA recognizes and creates a DNA break at the genomic target locus; and

(ii) the second polypeptide is a donor recruitment protein, wherein the donor recruitment protein comprises:

(1) a DNA binding domain that binds to the donor polynucleotide, and

(2) a DNA break site localizing domain that binds to a region near the DNA break at the genomic target locus;

wherein the donor recruitment protein when bound to both the region near the DNA break site and to the donor polynucleotide selectively recruits the donor polynucleotide to the DNA break site, thereby localizing the donor polynucleotide to the genomic target locus,

wherein the DNA binding domain comprises a LexA DNA binding domain and the DNA break site localizing domain comprises a forkhead-associated (FHA) phosphothreonine-binding domain or comprises a TP53BP1 domain.

2. The method of claim 1 , wherein the RNA-guided nuclease modifies the genomic target locus by integrating the donor polynucleotide into the genomic target locus, thereby producing a genetically engineered cell.

3. The method of claim 1 , wherein the genome editing cassette comprises a unique polynucleotide barcode or the donor polynucleotide comprises a unique polynucleotide barcode.

4. The method of claim 1 , wherein the RNA-guided nuclease is a Cas nuclease or an engineered RNA-guided FokI-nuclease.

5. The method of claim 4 , wherein the Cas nuclease is Cas9 or Cpf1.

6. The method of claim 1 , wherein the donor recruitment protein exists independent of the first RNA-guided nuclease.

7. The method of claim 1 , wherein the recruitment protein comprises a LexA DNA binding domain linked to the DNA break site localizing domain comprising an FHA phosphothreonine-binding domain.

8. The method of claim 1 , wherein the first recombinant polynucleotide is circular and further comprises a second nucleic acid sequence encoding a second gRNA (guide X) capable of hybridizing with the first recombinant polynucleotide, wherein the guide X forms a complex with a nuclease in each cell such that the guide X-nuclease complex cleaves the first recombinant polynucleotide.

9. The method of 2 , wherein the genetically engineered cell is a genetically engineered therapeutic cell.

10. The method of 9 , wherein the genetically engineered therapeutic cell is a genetically engineered immune cell.

11. The method of 10 , wherein the genetically engineered immune cell is a T cell or a natural killer cell that targets a cancer.

12. The method of claim 3 , wherein the target cell is modified to harbor a barcode integration locus for integration of the unique polynucleotide barcode.

13. A kit comprising the first recombinant polynucleotide and the second recombinant polynucleotide used in the method of claim 1 .

14. A method for localizing a donor polynucleotide to a genomic target locus in a target cell, the method comprising:

(a) transfecting a target cell with a first recombinant polynucleotide, the first recombinant polynucleotide comprising a genome editing cassette comprising:

(i) a promoter operably linked to a nucleic acid sequence encoding a guide RNA (gRNA) capable of hybridizing at a genomic target locus to be modified, and

(ii) a donor polynucleotide comprising a sequence to be integrated into the genomic target locus;

(b) transfecting the target cell with a second recombinant polynucleotide that encodes a first polypeptide and encodes a second polypeptide, wherein:

(i) the first polypeptide is an RNA-guided nuclease, wherein the RNA-guided nuclease when complexed with the gRNA recognizes and creates a DNA break site at the genomic target locus; and

(ii) the second polypeptide is a donor recruitment protein, wherein the donor recruitment protein comprises:

(1) a DNA binding domain that binds to the donor polynucleotide, and

(2) a DNA break site localizing domain that binds to a region near the DNA break at the genomic target locus;

wherein the donor recruitment protein when bound to both the region near the DNA break site and to the donor polynucleotide selectively recruits the donor polynucleotide to the DNA break site, thereby localizing the donor polynucleotide to the genomic target locus; and

wherein the genome editing cassette comprises a unique polynucleotide barcode or the donor polynucleotide comprises a unique polynucleotide barcode.

15. A method for localizing a donor polynucleotide to a genomic target locus in a target cell, the method comprising:

(a) transfecting a target cell with a first recombinant polynucleotide, the first recombinant polynucleotide comprising a genome editing cassette comprising:

(i) a promoter operably linked to a nucleic acid sequence encoding a guide RNA (gRNA) capable of hybridizing at a genomic target locus to be modified, and

(ii) a donor polynucleotide comprising a sequence to be integrated into the genomic target locus;

(b) transfecting the target cell with a second recombinant polynucleotide that encodes a first polypeptide and encodes a second polypeptide, wherein:

(i) the first polypeptide is an RNA-guided nuclease, wherein the RNA-guided nuclease when complexed with the gRNA recognizes and creates a DNA break site at the genomic target locus; and

(ii) the second polypeptide is a donor recruitment protein, wherein the donor recruitment protein comprises:

(1) a DNA binding domain that binds to the donor polynucleotide, and

(2) a DNA break site localizing domain that binds to a region near the DNA break at the genomic target locus;

wherein the donor recruitment protein when bound to both the region near the DNA break site and to the donor polynucleotide selectively recruits the donor polynucleotide to the DNA break site, thereby localizing the donor polynucleotide to the genomic target locus; and

wherein the first recombinant polynucleotide is circular and further comprises a second nucleic acid sequence encoding a second gRNA (guide X) capable of hybridizing with the first recombinant polynucleotide, wherein the guide X forms a complex with a nuclease in each cell such that the guide X-nuclease complex cleaves the first recombinant polynucleotide.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 7, 2022
From: HABER, JAMES E
To: BRANDEIS UNIVERSITY
Reel/Frame 059185/0285 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 14, 2022
From: SMITH, JUSTIN D., MR.; ROY, KEVIN, MR.; STEINMETZ, LARS M., MR.
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Reel/Frame 058656/0436 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 22, 2021
From: ST. ONGE, ROBERT P.
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Reel/Frame 058181/0062 →
Continuity (2)
Provisional Application 62559493 · Sep 15, 2017
Related Publication 20200270632A1 · Aug 27, 2020
References Cited (291)
US 4415732A · Caruthers et al. · 1983 [cited by applicant]
US 4458066A · Caruthers et al. · 1984 [cited by applicant]
US 4816567A · Cabilly et al. · 1989 [cited by applicant]
US 5122458A · Post et al. · 1992 [cited by applicant]
US 5135855A · Moss et al. · 1992 [cited by applicant]
US 5139941A · Muzyczka et al. · 1992 [cited by applicant]
US 5168062A · Stinski · 1992 [cited by applicant]
US 5173414A · Lebkowski et al. · 1992 [cited by applicant]
US 5219740A · Miller et al. · 1993 [cited by applicant]
US 5385839A · Stinski · 1995 [cited by applicant]
US 5676950A · Small et al. · 1997 [cited by applicant]
US 5789245A · Dubensky et al. · 1998 [cited by applicant]
US 5831005A · Zuckerman et al. · 1998 [cited by applicant]
US 5840051A · Towsley · 1998 [cited by applicant]
US 5843723A · Dubensky et al. · 1998 [cited by applicant]
US 5844107A · Hanson et al. · 1998 [cited by applicant]
US 5877278A · Zuckermann et al. · 1999 [cited by applicant]
US 5877302A · Hanson et al. · 1999 [cited by applicant]
US 5972900A · Ferkol et al. · 1999 [cited by applicant]
US 5972901A · Ferkol et al. · 1999 [cited by applicant]
US 5977301A · Zuckerman et al. · 1999 [cited by applicant]
US 6008336A · Hanson et al. · 1999 [cited by applicant]
US 6077835A · Hanson et al. · 2000 [cited by applicant]
US 6200801B1 · Ferkol et al. · 2001 [cited by applicant]
US 20020150626A1 · Kohane et al. · 2002 [cited by applicant]
US 20030032615A1 · Felgner et al. · 2003 [cited by applicant]
US 20030203865A1 · Harvie et al. · 2003 [cited by applicant]
US 20040048787A1 · Cooper et al. · 2004 [cited by applicant]
US 20040133138A1 · Modglin · 2004 [cited by applicant]
US 20100137143A1 · Rothberg et al. · 2010 [cited by applicant]
US 20100304982A1 · Hinz et al. · 2010 [cited by applicant]
US 20110105971A1 · Ingimundarson et al. · 2011 [cited by applicant]
US 20150031132A1 · Church et al. · 2015 [cited by applicant]
US 20160122748A1 · St. onge et al. · 2016 [cited by applicant]
US 20160228279A1 · Modglin et al. · 2016 [cited by applicant]
US 20170058298A1 · Kennedy et al. · 2017 [cited by applicant]
US 20170233765A1 · Kay · 2017 [cited by examiner]
US 20190085356A1 · Xia et al. · 2019 [cited by applicant]
CN 106133138A · 2016 [cited by applicant]
DE 10329454A1 · 2005 [cited by applicant]
EP 3024964A2 · 2016 [cited by applicant]
GB 2276169A · 1994 [cited by applicant]
WO 8903429A1 · 1989 [cited by applicant]
WO 9112882A1 · 1991 [cited by applicant]
WO 9201070A1 · 1992 [cited by applicant]
WO 9203545A1 · 1992 [cited by applicant]
WO 9303769A1 · 1993 [cited by applicant]
WO 9426911A1 · 1994 [cited by applicant]
WO 9507995A2 · 1995 [cited by applicant]
WO 9617072A2 · 1996 [cited by applicant]
WO 0061772A2 · 2000 [cited by applicant]
WO 0071096A2 · 2000 [cited by applicant]
WO 0181609A2 · 2001 [cited by applicant]
WO 02080982A2 · 2002 [cited by applicant]
WO 02099035A2 · 2002 [cited by applicant]
WO 2015013583A2 · 2015 [cited by applicant]
WO 2015095804A1 · 2015 [cited by applicant]
WO 2016183448A1 · 2016 [cited by applicant]
WO WO2016176404A1 · 2016 [cited by examiner]
WO WO2017070056A1 · 2017 [cited by examiner]
WO 2017092201A1 · 2017 [cited by applicant]
WO 2017223538A1 · 2017 [cited by applicant]
WO 2019051240A1 · 2019 [cited by applicant]
Shan, Targeted genome modification of crop plants using a CRISPR-Cas system, Nature Biotechnology, vol. 31, No. 8, Aug. 2013 (Year: 2013). [cited by examiner]
Gupta, Expanding the genetic editing tool kit: ZFNs, TALENs, and CRISPR-Cas9, The Journal of Clinical Investigation, 2014; 124(10) (Year: 2014). [cited by examiner]
Nagasaki, Enhanced nuclear import and transfection efficiency of plasmid DNA using streptavidin-fused importin-Beta, Journal of Controlled Release, 103 (2005), pp. 199-207 (Year: 2005). [cited by examiner]
Li, Jin, et al. “Regulation of budding yeast mating-type switching donor preference by the FHA domain of Fkh1.” PLoS genetics 8.4 (2012): e1002630. (Year: 2012). [cited by examiner]
“DIY Bacterial Gene Engineering Crispr Kit.” The ODIN, 2017, www.the-odin.com/diy-crispr-kit/. Accessed Feb. 12, 2024. (Year: 2017). [cited by examiner]
Bolukbasi, Mehmet Fatih, et al. “DNA-binding-domain fusions enhance the targeting range and precision of Cas9.” Nature methods 12.12 (2015): 1150-1156. (Year: 2015). [cited by examiner]
Bonilla, Braulio, et al. “RAD51 gene family structure and function.” Annual review of genetics 54 (2020): 25-46. (Year: 2020). [cited by examiner]
Tarantola, A. (Jun. 30, 2016). I played god with the Odin's DIY CRISPR kit. Engadget. https://www.engadget.com/2016-06-30-i-played-god-with-the-odins-diy-crispr-kit.html (Year: 2016). [cited by examiner]
Lee, Kunwoo, et al. “Synthetically modified guide RNA and donor DNA are a versatile platform for CRISPR-Cas9 engineering.” elife 6 (2017): e25312. (Year: 2017). [cited by examiner]
Schumann, Kathrin, et al. “Generation of knock-in primary human T cells using Cas9 ribonucleoproteins.” Proceedings of the National Academy of Sciences 112.33 (2015): 10437-10442. (Year: 2015). [cited by examiner]
Dou, Hong, Sankar Mitra, and Tapas K. Hazra. “Repair of oxidized bases in DNA bubble structures by human DNA glycosylases NEIL1 and NEIL2.” Journal of Biological Chemistry 278.50 (2003): 49679-49684. (Year: 2003). [cited by examiner]
“DEF1 DNA Damage-Responsive RNA Polymerase-Degradation Factor Def1 [ [cited by examiner]
“TPA: DNA Damage-Responsive RNA Polymerase-Degradation Factor DEF1 [SAC—Protein—NCBI.” National Center for Biotechnology Information, U.S. National Library of Medicine, Jan. 23, 2024, www.ncbi.nlm.nih.gov/protein/285813… [cited by examiner]
Wang, Baosheng, et al. “Maize defensin ZmDEF1 is involved in plant response to fungal phytopathogens.” African Journal of Biotechnology 10.72 (2011): 16128-16137. (Year: 2011). [cited by examiner]
Ma, Ming, et al. “Efficient generation of mice carrying homozygous double-floxp alleles using the Cas9-Avidin/Biotin-donor DNA system.” Cell Research 27.4 (2017): 578-581. (Year: 2017). [cited by examiner]
Bao et al. (May 15, 2015) “Homology-Integrated CRISPR-Cas (HI-CRISPR) System for One-Step Multigene Disruption in [cited by applicant]
Baranick et al. (Mar. 25, 2008) “Splicing Mediates the Activity of Four Putative Cellular Internal Ribosome Entry Sites”, Proceedings of the National Academy of Sciences of the United States of America, 105(12):4733-473… [cited by applicant]
Beaucage et al. (Mar. 20, 1992) “Advances in the Synthesis of Oligonucleotides by the Phosphoramidite Approach”, Tetrahedron, 48(12):2223-2311. [cited by applicant]
Bentley et al. (Nov. 6, 2008) “Accurate Whole Human Genome Sequencing Using Reversible Terminator Chemistry”, Nature, 456(7218):53-59. [cited by applicant]
Benvenisty et al. (Dec. 1986) “Direct Introduction of Genes into Rats and Expression of the Genes”, Proceedings of the National Academy of Sciences of the United States of America, Dec. 1986, 83(24):9551-9555. [cited by applicant]
Bert et al. (Apr. 6, 2006) “Assessing IRES Activity in the HIF-1α and Other Cellular 5′ UTRs”, RNA, 12(6):1074-1083. [cited by applicant]
Bett et al. (Oct. 1993) “Packaging Capacity and Stability of Human Adenovirus Type Vectors”, Journal of Virology, 67(10):5911-5921. [cited by applicant]
Birling et al. (May 15, 2009) “Site-Specific Recombinases for Manipulation of The Mouse Genome”, Methods in Molecular Biology, 561:245-263. [cited by applicant]
Boris-Lawrie et al. (Feb. 1993) “Recent Advances in Retrovirus Vector Technology”, Current Opinion in Genetics & Development, 3(1):102-109. [cited by applicant]
Boshart et al. (Jun. 1985) “A Very Strong Enhancer is Located Upstream of an Immediate Early Gene of Human Cytomegalovirus.”, Cell, 41(2):521-530. [cited by applicant]
Branda et al. (Jan. 2004) “Talking about a Revolution: The Impact of Site-Specific Recombinases on Genetic Analyses in Mice”, Developmental Cell, 6(1):7-28. [cited by applicant]
Brown et al. (1979) “Chemical Synthesis and Cloning of a Tyrosine TRNA Gene”, Methods in Enzymology, 68:109-151. [cited by applicant]
Bucholtz F. (May 29, 2008) “Principles of Site-Specific Recombinase (SSR) Technology”, Journal of Visualized Experiments, 15:652-658. [cited by applicant]
Burns et al. (Sep. 1, 1993) “Vesicular Stomatitis Virus G Glycoprotein Pseudotyped Retroviral Vectors: Concentration to Very High Titer and Efficient Gene Transfer into Mammalian and Nonmammalian Cells”, Proceedings of … [cited by applicant]
Carter Barrie J. (Oct. 1992) “Adeno-Associated Virus Vectors”, Current Opinion in Biotechnology, 3(5):533-539. [cited by applicant]
Chen et al. (Feb. 2, 1994) “A Self-Initiating Eukaryotic Transient Gene Expression System Based on Cotransfection of Bacteriophage T7 RNA Polymerase and DNA Vectors Containing a T7 Autogene”, Nucleic Acids Research, 22(… [cited by applicant]
Chen et al. (Aug. 1987) “High-Efficiency Transformation of Mammalian Cells by Plasmid DNA”, Molecular and Cellular Biology, 7(8):2745-2752. [cited by applicant]
Chu et al. (May 2015) “Increasing the Efficiency of Homology-Directed Repair for CRISPR-Cas9-Induced Precise Gene Editing in Mammalian Cells”, Nature Biotechnology, 33(5):543- 548. [cited by applicant]
Chu et al. (Mar. 1981) “SV40 DNA Transfection of Cells in Suspension: Analysis of Efficiency of Transcription and Translation of T-Antigen.”, Gene, 13(2):197-202. [cited by applicant]
Chylinski et al. (Jun. 2014) “Classification and Evolution of Type II CRISPR-Cas Systems”, Nucleic Acids Research, 42(10):6091-6105. [cited by applicant]
Cleary et al. (Dec. 2004) “Production of complex nucleic acid libraries using highly parallel in situ oligonucleotide synthesis”, Nature Methods, 1(3):241-248. [cited by applicant]
Cox et al. (Oct. 2001) “Automated Selection of Anti-Protein Aptamers”, Bioorganic & Medicinal Chemistry, 9(10):2525-2531. [cited by applicant]
Cox et al. (Oct. 15, 2002) “Automated Selection of Aptamers Against Protein Targets Translated in Vitro: From Gene to Aptamer”, Nucleic Acids Research, e108, 30(20):14 pages. [cited by applicant]
Deng et al. (Jun. 10, 1994) “Self-Amplifying Expression from the T7 Promoter in 3T3 Mouse Fibroblasts”, Gene, 143(2):245-249. [cited by applicant]
Desmet et al. (Oct. 30, 2014) “Structural basis of IL-23 antagonism by an Alphabody protein scaffold”, Nature Communications, 5(5237):1-12. [cited by applicant]
DiCarlo et al. (Apr. 2013) “Genome Engineering in [cited by applicant]
Dijkema et al. (Mar. 1985) “Cloning and Expression of the Chromosomal Immune Interferon Gene of the Rat”, The EMBO Journal, 4(3):761-767. [cited by applicant]
Dobrikova et al. (Dec. 9, 2003) “Activity of a Type 1 Picornavirus Internal Ribosomal Entry Site is Determined by Sequences within the 3 Nontranslated Region”, Proceedings of the National Academy of Sciences of the Unit… [cited by applicant]
Drmanac et al. (Jan. 1, 2010) “Human Genome Sequencing Using Unchained Base Reads on Self-Assembling DNA Nanoarrays”, Science, 327(5961):78-81. [cited by applicant]
Dubensky et al. (Dec. 1, 1984) “Direct Transfection of Viral and Plasmid DNA into the Liver or Spleen of Mice”, Proceedings of the National Academy of Sciences of the United States of America, 81(23):7529-7533. [cited by applicant]
Dubensky et al. (Jan. 1996) “Sindbis Virus DNA-Based Expression Vectors: Utility for in Vitro and in Vivo Gene Transfer”, Journal of Virology, 70(1):508-519. [cited by applicant]
Durand et al. (Feb. 2011) “The Inside Out of Lentiviral Vectors”, Viruses, 3(2):132-159. [cited by applicant]
Ebersbach et al. (Sep. 7, 2007) “Affilin—Novel Binding Molecules Based on Human γ-B-Crystallin, an All β-Sheet Protein”, Journal of Molecular Biology, 372(1):172-185. [cited by applicant]
Ehrlich et al. (Aug. 19, 1980) “Isolation of an Active Heavy-Chain Variable Domain from a Homogeneous Rabbit Antibody by Cathepsin B Digestion of the Aminoethylated Heavy Chain”, Biochemistry, 19(17):4091-4096. [cited by applicant]
Eid et al. (Jan. 2, 2009) “Real-time DNA Sequencing from Single Polymerase Molecules”, Science, 323(5910):133-138. [cited by applicant]
Elayadi et al. (Apr. 2001) “Application of PNA and LNA Oligomers to Chemotherapy”, Current Opinion in Investigational Drugs, 2(4):558-561. [cited by applicant]
Elroy-Stein et al. (Sep. 1990) “Cytoplasmic Expression System Based on Constitutive Synthesis of Bacteriophage T7 RNA Polymerase in Mammalian Cells”, Proceedings of the National Academy of Sciences of the United States … [cited by applicant]
Fechheimer et al. (Dec. 1, 1987) “Transfection of Mammalian Cells with Plasmid DNA by Scrape Loading and Sonication Loading”, Proceedings of the National Academy of Sciences of the United States of America, 84(23):8463-… [cited by applicant]
Ferkol et al. (Aug. 1, 1993) “Regulation of the Phosphoenolpyruvate Carboxykinase/Human Factor IX Gene Introduced into the Livers of Adult Rats by Receptor-Mediated Gene Transfer”, The FASEB Journal, 7(11):1081-1091. [cited by applicant]
Ferry et al. (2011) “Retroviral Vector-mediated Gene Therapy for Metabolic Diseases: An Update”, Current Pharmaceutical Design, 17(24):2516-2517. [cited by applicant]
Fonfara et al. (Feb. 2014) “Phylogeny of Cas9 Determines Functional Exchangeability of Dual-RNA and Cas9 Among Orthologous Type II CRISPR-Cas Systems”, Nucleic Acids Research, 42(4):2577-2590. [cited by applicant]
Fraley et al. (Jul. 1, 1979) “Entrapment of a Bacterial Plasmid in Phospholipid Vesicles: Potential for Gene Transfer”, Proceedings of the National Academy of Sciences of the United States of America, 76(7):3348-3352. [cited by applicant]
Fuerst et al. (Nov. 1, 1986) “Eukaryotic Transient-Expression System Based on Recombinant Vaccinia Virus that Synthesizes Bacteriophage T7 RNA Polymerase”, Proceedings of the National Academy of Sciences of the United S… [cited by applicant]
Furler et al. (Jun. 22, 2001) “Recombinant AAV Vectors Containing the Foot and Mouth Disease Virus 2A Sequence Confer Efficient Bicistronic Gene Expression in Cultured Cells and Rat Substantia Nigra Neurons”, Gene Thera… [cited by applicant]
Gaj et al. (Jan. 2014) “Expanding the Scope of Site-Specific Recombinases for Genetic and Metabolic Engineering”, Biotechnology and Bioengineering, 111(1):1-15. [cited by applicant]
Gao et al. (May 15, 1994) “A Sustained, Cytoplasmic Transgene Expression System Delivered by Cationic Liposomes”, Biochemical and Biophysical Research Communications, 200(3):1201-1206. [cited by applicant]
Gao et al. (Jun. 25, 1993) “Cytoplasmic Expression of a Reporter Gene by Co-Delivery of T7 RNA Polymerase and T7 Promoter Sequence with Cationic Liposomes”, Nucleic Acids Research, 21(12):2867-2872. [cited by applicant]
Garcia-Otin et al. (Jan. 1, 2006) “Mammalian Genome Targeting Using Site-Specific Recombinases”, Frontiers in Bioscience, 11:1108-1136. [cited by applicant]
Garlapati et al. (Jan. 30, 2004) “Identification of a Novel Internal Ribosome Entry Site in Giardiavirus That Extends to Both Sides of the Initiation Codon”, Journal of Biological Chemistry, 279(5):3389-3397. [cited by applicant]
Garst et al. (Dec. 12, 2016) “Genome-Wide Mapping of Mutations at Single-Nucleotide Resolution for Protein, Metabolic and Genome Engineering”, Nature Biotechnology, 35(1):48-55. [cited by applicant]
Gilbert et al. (Oct. 23, 2014) “Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation”, Cell, 159(3):647-661. [cited by applicant]
Glenn et al. (Sep. 2011) “Field Guide to Next-Generation DNA Sequencers”, Molecular Ecology Resources, 11(5):759-769. [cited by applicant]
Gopal Venkatt. (May 1985) “Gene Transfer Method for Transient Gene Expression, Stable Transformation, and Cotransformation of Suspension Cell Cultures”, Molecular and Cellular Biology, 5(5):1188-1190. [cited by applicant]
Gorman et al. (Nov. 1, 1982) “The Rous Sarcoma Virus Long Terminal Repeat is a Strong Promoter when Introduced into a Variety of Eukaryotic Cells by DNA-Mediated Transfection”, Proceedings of the National Academy of Sci… [cited by applicant]
Grabulovski et al. (Mar. 2007) “A Novel, Non-immunogenic Fyn SH3-derived Binding Protein with Tumor Vascular Targeting Properties”, Journal of Biological Chemistry, 282(5):3196-3204. [cited by applicant]
Graham et al. (Apr. 1973) “A New Technique for the Assay of Infectivity of Human Adenovirus 5 DNA”, Virology, 52(2):456-467. [cited by applicant]
Greco et al. (May 5, 2015) “Improving the Safety of Cell Therapy With the TK-Suicide Gene”, Frontiers in Pharmacology, 6:13 pages. [cited by applicant]
Gurtu et al. (Dec. 4, 1996) “IRES bicistronic expression vectors for efficient creation of stable mammalian cell lines”, Biochemical and Biophysical Research Communications, 229(1):295-298. [cited by applicant]
Hackland et al. (1994) “Coat Protein-Mediated Resistance in Transgenic Plants”, Archives of Virology, 139(1-2):1-22. [cited by applicant]
Haj-Ahmad et al. (Jan. 1986) “Development of a Helper-Independent Human Adenovirus Vector and Its Use in the Transfer of the Herpes Simplex Virus Thymidine Kinase Gene”, Journal of Virology, 57(1):267-274. [cited by applicant]
Harland et al. (Sep. 1, 1985) “Translation of MRNA Injected into Xenopus Oocytes is Specifically Inhibited by Antisense RNA”, Journal of Cell Biology, 101(3):1094-1099. [cited by applicant]
Havlicek et al. (Feb. 1, 2017) “Re-engineered RNA-Guided Fokl-Nucleases for Improved Genome Editing in Human Cells”, Molecular Therapy, 25(2):342-355. [cited by applicant]
Huston et al. (Aug. 1, 1988) “Protein Engineering of Antibody Binding Sites: Recovery of Specific Activity in an Anti-Digoxin Single-Chain Fv Analogue Produced in [cited by applicant]
Inbar et al. (Sep. 1, 1972) “Localization of Antibody-Combining Sites within the Variable Portions of Heavy and Light Chains”, Proceedings of the National Academy of Sciences of the United States of America, 69(9);2659-… [cited by applicant]
Jakočiūna et al. (Mar. 2015) “Multiplex Metabolic Pathway Engineering Using CRISPR/Cas9 In [cited by applicant]
Jang et al. (Apr. 1989) “Initiation of protein synthesis by internal entry of ribosomes into the 5′ nontranslated region of encephalomyocarditis virus RNA in vivo.”, Journal of Virology, 63(4):1651-1660. [cited by applicant]
Jinek et al. (Aug. 17, 2012) “A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity”, Science, 337(6069):816-821. [cited by applicant]
Johnson et al. (Jul. 26, 2012) “Sensitive affimer and antibody based impedimetric label-free assays for C-reactive protein”, Analytical Chemistry, 84(15):6553-6560. [cited by applicant]
Jones et al. (Nov. 27, 2014) “Improving the Safety of Cell Therapy Products by Suicide Gene Transfer”, Frontiers in Pharmacology, 5:8 pages. [cited by applicant]
Junemann et al. (Apr. 5, 2013) “Updating Benchtop Sequencing Performance Comparison”, Nature Biotechnology, 31(4):294-296. [cited by applicant]
Kaneda et al. (Jan. 20, 1989) “Increased Expression of DNA Cointroduced with Nuclear Protein in Adult Rat Liver”, Science, 243(4889):375-378. [cited by applicant]
Kapitonov et al. (Dec. 28, 2015) “ISC, a Novel Group of Bacterial and Archaeal DNA Transposons That Encode Cas9 Homologs”, Journal of Bacteriology, 198(5):797-807. [cited by applicant]
Kato et al. (Feb. 25, 1991) “Expression of Hepatitis B Virus Surface Antigen in Adult Rat Liver. Co-Introduction of DNA and Nuclear Protein by a Simplified Liposome Method”, Journal of Biological Chemistry, 266(6):3361-… [cited by applicant]
Kaufman et al. (Aug. 25, 1991) “Improved vectors for stable expression of foreign genes in mammalian cells by use of the untranslated leader sequence from EMC virus”, Nucleic Acids Research, 19(16):4485-4490. [cited by applicant]
Kenan et al. (1999) “In Vitro Selection of Aptamers from RNA Libraries”, Methods in Molecular Biology, 118:217-231. [cited by applicant]
Kim et al. (Apr. 29, 2011) “High Cleavage Efficiency of a 2A Peptide Derived from Porcine Teschovirus-1 in Human Cell Lines, Zebrafish and Mice”, PLoS One, e18556, 6(4):8 pages. [cited by applicant]
Kim et al. (Jun. 8, 2007) “Polony Multiplex Analysis of Gene Expression (PMAGE) in Mouse Hypertrophic Cardiomyopathy”, Science, 316(5830):1481-1484. [cited by applicant]
Klein et al. (May 7, 1987) “High-Velocity Microprojectiles for Delivering Nucleic Acids into Living Cells”, Nature, 327:70-73. [cited by applicant]
Koide et al. (Feb. 2007) “Monobodies: Antibody Mimics Based on the Scaffold of the Fibronectin Type III Domain”, Methods in Molecular Biology, 352:95-109. [cited by applicant]
Koike-Yusa et al. (Mar. 2014) “Genome-Wide Recessive Genetic Screening in Mammalian Cells with a Lentiviral CRISPR-Guide RNA Library”, Nature Biotechnology, 32(3):267-273. [cited by applicant]
Kolb Andreas F. (2002) “Genome Engineering Using Site-Specific Recombinases”, Cloning Stem Cells, 4(1):65-80. [cited by applicant]
Konermann et al. (Jan. 29, 2015) “Genome-Scale Transcriptional Activation by an Engineered CRISPR-Cas9 Complex”, Nature, 517(7536):583-588. [cited by applicant]
Koshkin et al. (Apr. 2, 1998) “LNA (Locked Nucleic Acids): Synthesis of the Adenine, Cytosine, Guanine, 5-Methylcytosine, Thymine and Uracil Bicyclonucleoside Monomers, Oligomerisation, and Unprecedented Nucleic Acid Re… [cited by applicant]
Kotin Robertm. (Jul. 1994) “Prospects for the Use of Adeno-Associated Virus as a Vector for Human Gene Therapy”, Human Gene Therapy, 5(7):793-801. [cited by applicant]
Krappmann Sven. (Mar. 2014) “Genetic Surgery In Fungi: Employing Site-Specific Recombinases For Genome Manipulation”, Applied Microbiology and Biotechnology, 98(5):1971-1982. [cited by applicant]
Krehenbrink et al. (Nov. 28, 2008) “Artificial binding proteins (Affitins) as probes for conformational changes in secretin PulD”, Journal of Molecular Biology, 383(5):1058-1068. [cited by applicant]
Kurreck et al. (May 1, 2002) “Design of Antisense Oligonucleotides Stabilized by Locked Nucleic Acids”, Nucleic Acids Research, 30(9):1911-1918. [cited by applicant]
Lebkowski et al. (Oct. 1988) “Adeno-associated virus: a vector system for efficient introduction and integration of DNA into a variety of mammalian cell types”, Molecular and Cellular Biology, 8(10):3988-3996. [cited by applicant]
Ledford Heidi. (Oct. 1, 2015) “Bacteria Yield New Gene Cutter”, Molecular Biology, 526(7571):17. [cited by applicant]
Li et al. (Apr. 2012) “Regulation of Budding Yeast Mating-Type Switching Donor Preference by the FHA Domain of Fkh1”, PLoS Genetics, 8(4):e1002630:14 pages. [cited by applicant]
Lin et al. (Oct. 2016) “Increasing the Efficiency of CRISPR/Cas9-mediated Precise Genome Editing of HSV-1 Virus in Human Cells”, Scientific Reports, 6(1):13 pages. [cited by applicant]
Lois et al. (Feb. 1, 2002) “Germline Transmission and Tissue-Specific Expression of Transgenes Delivered by Lentiviral Vectors”, Science, 295(5556):868-872. [cited by applicant]
Lopatniuk et al. (Mar. 24, 2015) “Testing the Utility of Site-Specific Recombinases For Manipulations of Genome of Moenomycin Producer [cited by applicant]
Lundstrom et al. (Mar. 2003) “Latest development in viral vectors for gene therapy”, Trends Biotechnology, 21(3):117-122. [cited by applicant]
Lyu et al. (2016) “Generating Cell Targeting Aptamers for Nanotheranostics Using Cell-SELEX”, Theranostics, 6(9):1440-1452. [cited by applicant]
Margulies et al. (Sep. 15, 2005) “Genome sequencing in microfabricated high-density picolitre reactors”, Nature, 437:376-380. [cited by applicant]
Martin et al. (Dec. 30, 2003) “Translation of the Human Angiotensin II Type 1 Receptor mRNA is Mediated by a Highly Efficient Internal Ribosome Entry Site”, Molecular and Cellular Endocrinology, 212(1-2):51-61. [cited by applicant]
Martineau et al. (Sep. 2004) “Internal Ribosome Entry Site Structural Motifs Conserved among Mammalian Fibroblast Growth Factor 1 Alternatively Spliced mRNAs”, Molecular and Cell Biology, 24(17):7622-7635. [cited by applicant]
Maruyama et al. (May 2015) “Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining”, National Biotechnology, 33(5):538-542. [cited by applicant]
Michael et al. (Apr. 5, 1993) “Binding-Incompetent Adenovirus Facilitates Molecular Conjugate-Mediated Gene Transfer by the Receptor-Mediated Endocytosis Pathway”, The Journal of Biological Chemistry, 268(10):6866-6869. [cited by applicant]
Miller et al. (Oct. 7, 1989) “Improved Retroviral Vectors for Gene Transfer and Expression”, Biotecniques, 7(9):980-990. [cited by applicant]
Miller A. Dusty. (1990) “Retrovirus Packaging Cells”, Human Gene Therapy, 1(1):5-14. [cited by applicant]
Mitsui et al. (Jun. 16, 2017) “Viral Vector-Based Innovative Approaches to Directly Abolishing Tumorigenic Pluripotent Stem Cells for Safer Regenerative Medicine”, Molecular Therapy Methods & Clinical Developments, 5:51… [cited by applicant]
Mittereder et al. (Jun. 1994) “Adenovirus-Mediated Transfer of the Human Cystic Fibrosis Transmembrane Conductance Regulator cDNA”, Human Gene Therapy, 5(6):717-729. [cited by applicant]
Moffatt et al. (May 5, 1986) “Use of Bacteriophage T7 RNA Polymerase to Direct Selective High-Level Expression of Cloned Genes”, Journal of Molecular Biology, 189(1):113-130. [cited by applicant]
Mosser et al. (1997) “Use of a Dicistronic Expression Cassette Encoding the Green Fluorescent Protein for the Screening and Selection of Cells Expressing Inducible Gene Products”, BioTechniques, 22(1):150-161. [cited by applicant]
Murovec et al. (Aug. 2017) “New Variants of CRISPR RNA-Guided Genome Editing Enzymes”, Plant Biotechnology Journal, 15(8):917-926. [cited by applicant]
Muzyczka N (1992) “Use of Adeno-Associated Virus as a General Transduction Vector for Mammalian Cells”, Current Topics in Microbiology and Immunology, 158:97-129. [cited by applicant]
Narang et al. (1979) “Improved phosphotriester method for the synthesis of gene fragments”, Methods in Enzymology, 8:90-98. [cited by applicant]
NCBI (May 4, 2021) “Belliella Baltica Dsm 15883, Complete Sequence”, NCBI Accession No. NC_018010.1, 2 pages. [cited by applicant]
NCBI (Jan. 31, 2021) “Corynebacterium Diphtheriae 241, Complete Sequence”, NCBI Accession No. NC_016782.1, 2 pages. [cited by applicant]
NCBI (Feb. 7, 2021) “Corynebacterium Diphtheriae Hc01, Complete Sequence”, NCBI Accession No. NC_016786.1, 2 pages. [cited by applicant]
NCBI (Jan. 17, 2021) “Corynebacterium Ulcerans 809, Complete Sequence”, NCBI Accession No. NC_017317.1, 2 pages. [cited by applicant]
NCBI (Jan. 17, 2021) “Corynebacterium Ulcerans Br-ad22, Complete Sequence”, NCBI Accession No. NC_015683.1, 2 pages. [cited by applicant]
NCBI (Aug. 3, 2016) “Crispr-Associated Protein [ [cited by applicant]
NCBI (Dec. 16, 2014) “Crispr-System-like Protein [ [cited by applicant]
NCBI (Oct. 29, 2018) “Hypothetical Protein [campylobacter Fetus]”, NCBI Accession No. WP_059434633.1, 1 page. [cited by applicant]
NCBI (Dec. 17, 2014) “Hypothetical Protein Lin2744 [listeria Innocua Clip11262]”, NCBI Accession No. NP_472073.1, 2 pages. [cited by applicant]
NCBI (Dec. 16, 2014) “Hypothetical Protein Nma0631 [neisseria Meningitidis Z2491]”, NCBI Accession No. YP_002342100.1, 2 pages. [cited by applicant]
NCBI (Oct. 9, 2019) “Multispecies: Type II Crispr Rna-guided Endonuclease Cas9 [campylobacter]”, NCBI Accession No. WP_022552435.1, 2 pages. [cited by applicant]
NCBI (Nov. 28, 2020) “Prevotella Intermedia 17 Chromosome II, Complete Sequence”, NCBI Accession No. NC_017861.1, 2 pages. [cited by applicant]
NCBI, (May 4, 2021) “Psychroflexus Torquis Atcc 700755, Complete Sequence”, NCBI Accession No. NC_018721.1, 2 pages. [cited by applicant]
NCBI (Jan. 24, 2021) “Spiroplasma Syrphidicola Ea-1, Complete Sequence”, NCBI Accession No. NC_021284.1, 2 pages. [cited by applicant]
NCBI (Jan. 24, 2021) “Spiroplasma Taiwanense Ct-1, Complete Sequence”, NCBI Accession No. NC_021846.1 2 pages. [cited by applicant]
NCBI (Dec. 18, 2014) “ [cited by applicant]
NCBI (Oct. 9, 2019) “Type II Crispr Rna-guided Endonuclease Cas9 [ [cited by applicant]
NCBI (Oct. 9, 2019) “Type II Crispr Rna-guided Endonuclease Cas9 [enterococcus Faecalis]”, NCBI Accession No. WP_033919308.1, 2 pages. [cited by applicant]
NCBI (Oct. 9, 2019) “Type II Crispr Rna-Guided Endonuclease Cas9 [lacticaseibacillus Rhamnosus]”, NCBI Accession No. WP_032965177.1, 2 pages. [cited by applicant]
NCBI (Oct. 9, 2019) “Type II Crispr Rna-Guided Endonuclease Cas9 [lactobacillus Rhamnosus]”, NCBI Accession No. WP_048482595.1, 2 pages. [cited by applicant]
NCBI (Oct. 9, 2019) “Type II Crispr Rna-guided Endonuclease Cas9 [listeria Monocytogenes]”, NCBI Accession No. WP_061665472.1, 2 pages. [cited by applicant]
NCBI (Oct. 9, 2019) “Type II Crispr Rna-Guided Endonuclease Cas9 [neisseria Meningitidis]”, NCBI Accession No. WP_061704949.1, 2 pages. [cited by applicant]
NCBI (Oct. 9, 2019) “Type II Crispr Rna-Guided Endonuclease Cas9 [ [cited by applicant]
NCBI (Oct. 9, 2019) “Type II Crispr Rna-guided Endonuclease Cas9 [ [cited by applicant]
NCBI (Oct. 9, 2019) “Type II Crispr Rna-guided Endonuclease Cas9 [ [cited by applicant]
NCBI (Oct. 9, 2019) “Type II Crispr Rna-guided Endonuclease Cas9 [ [cited by applicant]
NCBI (Oct. 9, 2019) “Type II Crispr Rna-guided Endonuclease Cas9 [ [cited by applicant]
NCBI, (Oct. 9, 2019) “Type II Crispr Rna-guided Endonuclease Cas9 [ [cited by applicant]
NCBI (Jun. 20, 2019) “Type II-B CRISPR-Associated RNA-Guided Endonuclease Cas9/Csx12 [Francisella hispaniensis]”, NCBI Accession No. WP_014548420.1, 2 pages. [cited by applicant]
NCBI (Jun. 20, 2019) “Type II-B Crispr-Associated Rna-Guided Endonuclease Cas9/csx12 [francisella Tularenisis]”, NCBI Accession No. WP_032729892.1, 2 pages. [cited by applicant]
NCBI (Jun. 19, 2019) “Type II-B Crispr-associated Rna-Guided Endonuclease Cas9/csx12 [legionella Pneumophila]”, NCBI Accession No. WP_062726656.1, 2 pages. [cited by applicant]
Nern et al. (Aug. 23, 2011) “Multiple new site-specific recombinases for use in manipulating animal genomes”, Proceedings of the National Academy of Sciences of the United States of America, 108(34):14198-14203. [cited by applicant]
Nguyen et al. (Jul. 1, 2000) “Improving SH3 Domain Ligand Selectivity Using a Non-Natural Scaffold”, Chemistry & Biology, 7(7):463-473. [cited by applicant]
Nicolau et al. (1987) “[16]Lipsomes as Carriers for in Vivo Gene Transfer and Expression”, Methods in Enzymology, 149:157-176. [cited by applicant]
Nicolau et al. (Oct. 11, 1982) “Liposome-Mediated DNA Transfer in Eukaryotic Cells. Dependence of the Transfer Efficiency Upon the Type of Liposomes Used and the Host Cell Cycle Stage”, Biochimica et Biophysica Acta, 72… [cited by applicant]
Nygren Per-Ake. (Jun. 2008) “Alternative binding proteins: affibody binding proteins developed from a small three-helix bundle scaffold”, The FEBS Journal, 275(11):2668-2676. [cited by applicant]
Obika et al. (Jul. 23, 1998) “Stability and Structural Features of the Duplexes Containing Nucleoside Analogues with a Fixed N-type Conformation, 2′-o,4′-c-methyleneribonucleosides”, Tetrahedron Letters, 39(30):5401-540… [cited by applicant]
Pack et al. (Feb. 18, 1992) “Miniantibodies: use of amphipathic helices to produce functional, flexibly linked dimeric FV fragments with high avidity in [cited by applicant]
Pan et al. (Oct. 2016) “CRISPR RNA-Guided Fokl Nucleases Repair a PAH Variant in a Phenylketonuria Model”, Scientific Reports, 6(1):7 pages. [cited by applicant]
Pedersen et al. (Apr. 1, 2002) “Human Insulin-like Growth Factor II Leader 2 Mediates Internal Initiation of Translation”, Biochemical Journal, 363(Pt 1):37-44. [cited by applicant]
Perales et al. (Apr. 1, 1994) “Gene Transfer In Vivo: Sustained Expression and Regulation of Genes Introduced into the Liver by Receptor-Targeted Uptake”, Proceedings of the National Academy of Sciences of the United St… [cited by applicant]
Perri et al. (Oct. 2003) “An Alphavirus Replicon Particle Chimera Derived from Venezuelan Equine Encephalitis and Sindbis Viruses is a Potent Gene-Based Vaccine Delivery Vector”, Journal of Virology, 77(19):10394-10403. [cited by applicant]
Porta et al. (Jun. 1, 1996) “Use of Viral Replicons for the Expression of Genes in Plants”, Molecular Biotechnology, 5(3):209-221. [cited by applicant]
Potter et al. (Nov. 1, 1984) “Enhancer-Dependent Expression of Human Kappa Immunoglobulin Genes Introduced into Mouse Pre-B Lymphocytes by Electroporation”, Proceedings of the National Academy of Sciences of the United … [cited by applicant]
Provost et al. (Oct. 2007) “Viral 2A peptides allow expression of multiple proteins from a single ORF in transgenic zebrafish embryos”, Genesis, 45(10):625-629. [cited by applicant]
Ramesh et al. (Jul. 1, 1996) “High-Riter Bicistronic Retroviral Vectors Employing Foot-and-Mouth Disease Virus Internal Ribosome Entry Site”, Nucleic Acids Research, 24(14):2697-2700. [cited by applicant]
Rees et al. (Jan. 1996) “Bicistronic vector for the creation of stable mammalian cell lines that predisposes all antibiotic-resistant cells to express recombinant protein”, BioTechniques, 20(1):102-110. [cited by applicant]
Rich et al. (Aug. 1993) “Development and Analysis of Recombinant Adenoviruses for Gene Therapy of Cystic Fibrosis”, Human Gene Therapy, 4(4):461-476. [cited by applicant]
Richardson et al. (Jan. 20, 2016) “Enhancing Homology-Directed Genome Editing by Catalytically Active and Inactive CRISPR-Cas9 Using Asymmetric Donor DNA”, Nature Biotechnology, 34(3):339-344. [cited by applicant]
Riechmann et al. (1988) “Reshaping Human Antibodies for Therapy”, Nature, Mar. 24, 332(6162):323-327. [cited by applicant]
Rippe et al. (Feb. 1990) “DNA-Mediated Gene Transfer into Adult Rat Hepatocytes in Primary Culture”, Molecular and Cellular Biology, 10(2):689-695. [cited by applicant]
Ronda et al., “Credit: CRISPR Mediated Multi-Loci Gene Integration In [cited by applicant]
Roy et al. (Jul. 2018) “Multiplexed Precision Genome Editing with Trackable Genomic Barcodes in Yeast”, Nature Biotechnology, 36(6):512-520. [cited by applicant]
Ryan et al. (2014) “Multiplex Engineering of Industrial Yeast Genomes Using Crisprm”, Methods in Enzymology, 546:473-489. [cited by applicant]
Ryan et al. (Aug. 19, 2014) “Selection of Chromosomal DNA Libraries Using a Multiplex CRISPR System”, eLife, 3:e03703:15 pages. [cited by applicant]
Scarpa et al. (Feb. 1991) “Characterization of Recombinant Helper Retroviruses from Moloney-Based Vectors in Ecotropic and Amphotropic Packaging Cell Lines”, Virology, 180(2):849-852. [cited by applicant]
Seth et al. (Feb. 1994) “Mechanism of enhancement of DNA expression consequent to cointernalization of a replication-deficient adenovirus and unmodified plasmid DNA”, Journal of Virology, 68(2):933-940. [cited by applicant]
Shalem et al. (Jan. 3, 2014) “Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells”, Science, 343(6166):84-87. [cited by applicant]
European Search Report received in EP Application No. 18856837.2, mailed on Apr. 22, 2021, 8 pages. [cited by applicant]
Shen et al. (Jul. 9, 2012) “Particlecall: A Particle Filter for Base Calling in Next-Generation Sequencing Systems”, BMC Bioinformatics, 13:11 pages. [cited by applicant]
Shmakov et al. (Nov. 5, 2015) “Discovery and Functional Characterization of Diverse Class 2 CRISPR-Cas Systems”, Molecular Cell, 60(3):385-397. [cited by applicant]
Silverman et al. (Nov. 20, 2005) “Multivalent Avimer Proteins Evolved by Exon Shuffling of a Family of Human Receptor Domains”, Nature Biotechnology, 23(12):1556-1561. [cited by applicant]
Simon et al. (Oct. 15, 1992) “Peptoids: A Modular Approach to Drug Discovery”, Proceedings of the National Academy of Sciences of the United States of America, 89(20):9367-9371. [cited by applicant]
Skerra Arne. (Jun. 2008) “Alternative Binding Proteins: Anticalins—Harnessing the Structural Plasticity of the Lipocalin Ligand Pocket to Engineer Novel Binding Activities”, The FEBS Journal, 275(11):2677-2683. [cited by applicant]
Smith et al. (Feb. 13, 2017) “A method for high-throughput production of sequence-verified DNA libraries and strain collections”, Molecular Systems Biology, 13(2):15 pages. [cited by applicant]
Smith et al. (Dec. 1981) “Comparison of Biosequences”, Advances in Applied Mathematics, 2(4):482-489. [cited by applicant]
Smith et al. (Apr. 2010) “Site-specific recombination by phiC31 integrase and other large serine recombinases”, Biochemical Society Transactions, 38(2):388-394. [cited by applicant]
Song et al. (Jan. 28, 2016) “RS-1 enhances CRISPR/Cas9- and TALEN-mediated knock-in efficiency”, Nature Communications, 7:7 pages. [cited by applicant]
Stein et al. (Jun. 1998) “Translation of vascular endothelial growth factor mRNA by internal ribosome entry: implications for translation under hypoxia”, Molecular and Cellular Biology, 18(6):3112-3119. [cited by applicant]
Stumpp et al. (Aug. 2008) “DARPins: a new generation of protein therapeutics”, Drug Discovery Today, 13(15-16):695-701. [cited by applicant]
Svensen et al. (Sep. 23, 2011) “Microarray Generation of Thousand-Member Oligonucleotide Libraries”, PLoS One, 6(9):e24906(8 pages). [cited by applicant]
Talas et al. (Jun. 30, 2017) “A Convenient Method to Pre-screen Candidate Guide RNAs for CRISPR/Cas9 Gene Editing by NHEJ-mediated Integration of a ‘Self-cleaving’ GFP-expression Plasmid”, DNA Research, 24(6):609-621. [cited by applicant]
Thudi et al. (Jan. 2012) “Current State-of-Art of Sequencing Technologies for Plant Genomics Research”, Briefings in Functional Genomics, 11(1):3-11. [cited by applicant]
Trichas et al. (Sep. 15, 2008) “Use of the viral 2A peptide for bicistronic expression in transgenic mice”, BMC Biology, 6(40):13 pages. [cited by applicant]
Tsai et al. (Jun. 2014) “Dimeric CRISPR RNA-Guided Fokl Nucleases for Highly Specific Genome Editing”, Nature Biotechnology, 32(6):569-576. [cited by applicant]
Turan et al. (Sep. 2, 2011) “Site-specific recombinases: from tag-and-target- to tag-and-exchange-based genomic modifications”, The Faseb Journal, 25:4088-4107. [cited by applicant]
Tur-Kaspa et al. (Feb. 1986) “Use of Electroporation to Introduce Biologically Active Foreign Genes into Primary Rat Hepatocytes”, Molecular and Cellular Biology, 6(2):716-718. [cited by applicant]
Verhoeyan et al. (Mar. 25, 1988) “Reshaping human antibodies: grafting an antilysozyme activity”, Science, 239(4847):1534-1536. [cited by applicant]
Vincke et al. (Aug. 2012) “Introduction to Heavy Chain Antibodies and Derived Nanobodies”, Methods in Molecular Biology, 911:15-26. [cited by applicant]
Wagner et al., Jul. 1, 1992, “Coupling of Adenovirus to Transferrin-Polylysine/DNA Complexes Greatly Enhances Receptor-Mediated Gene Delivery and Expression of Transfected Genes”, Proceedings of the National Academy of … [cited by applicant]
Wagner et al. (May 1990) “Transferrin-Polycation Conjugates as Carriers for DNA Uptake into Cells”, Proceedings of the National Academy of Sciences of the United States of America, 87(9):3410-3414. [cited by applicant]
Walther et al. (Aug. 2000) “Viral Vectors for Gene Transfer: A Review of Their Use in The Treatment of Human Diseases”, Drugs, 60(2):249-271. [cited by applicant]
Wang et al. (Jan. 3, 2014) “Genetic Screens in Human Cells Using the CRISPR-Cas9 System”, Science, 343(6166):80-84. [cited by applicant]
Wang et al. (Jul. 21, 2016) “Nanobody-Derived Nanobiotechnology Tool Kits or Diverse Biomedical and Biotechnology Applications”, International Journal of Nanomedicine, 11:3287-3303. [cited by applicant]
Wang et al. (May 29, 2018) “Systematic Evaluation of CRISPR-Cas Systems Reveals Design Principles for Genome Editing in Human Cells”, Genome Biology, 19(1):2 pages. [cited by applicant]
Warnock et al. (Apr. 2, 2011) “Introduction to Viral Vectors”, Methods in Molecular Biology, 737:1-25. [cited by applicant]
Winter et al. (Jan. 24, 1991) “Man-Made Antibodies”, Nature, 349(6307):293-299. [cited by applicant]
Wirth et al. (Oct. 2007) “Road to Precision: Recombinase-Based Targeting Technologies for Genome Engineering”, Current Opinion in Biotechnology, 18(5):411-419. [cited by applicant]
Wu et al. (Feb. 1, 1988) “Evidence for Targeted Gene Delivery to Hep G2 Hepatoma Cells in Vitro”, Biochemistry, 27(3):887-892. [cited by applicant]
Wu et al. (Dec. 1993) “Liver-Directed Gene Delivery”, Advanced Drug Delivery Reviews, 12(3):159-167. [cited by applicant]
Wu et al. (Apr. 5, 1987) “Receptor-Mediated in Vitro Gene Transformation by a Soluble DNA Carrier System”, The Journal of Biological Chemistry, 262(10):4429-4432. [cited by applicant]
Xie et al. (Dec. 28, 2007) “Distinct Roles of Chromatin-Associated Factors MDC1 and 53BP1 in Mammalian Double Strand Break Repair”, Molecular Cell, 28(6):1045-1057. [cited by applicant]
Yang et al. (Dec. 1, 1990) “In Vivo and In Vitro Gene Transfer to Mammalian Somatic Cells by Particle Bombardment”, Proceedings of the National Academy of Sciences of the United States of America, 87(24):9568-9572. [cited by applicant]
Zetsche et al. (Oct. 22, 2015) “Cpf1 is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System”, Cell, 163(3):759-771. [cited by applicant]
Zhang et al. (Feb. 14, 2017) “Progress in Genome Editing Technology and Its Application in Plants”, Frontiers in Plant Science, 8:17 pages. [cited by applicant]
Zhou et al. (Jun. 1, 1994) “Adeno-Associated Virus 2-Mediated High Efficiency Gene Transfer into Immature and Mature Subsets of Hematopoietic Progenitor Cells in Human Umbilical Cord Blood”, Journal of Experimental Medi… [cited by applicant]
Zhou et al. (May 22, 2014) “High-Throughput Screening of a CRISPR/Cas9 Library for Functional Genomics in Human Cells”, Nature, 509(7501):487-491. [cited by applicant]
International Search Report and Written Opinion received for PCT Application No. PCT/U82018/051240, mailed on Mar. 4, 2019, 12 pages. [cited by applicant]
Barr et al. (Jan. 1, 1994) “Efficient Catheter-Mediated Gene Transfer into the Heart Using Replication-Defective Adenovirus”, Gene Therapy, 1(1):51-58. (Abstract). [cited by applicant]
Cumber et al. (Jul. 1, 1992) “Comparative stabilities in vitro and in vivo of a recombinant mouse antibody FvCys fragment and a bisFvCys conjugate”, The Journal of Immunology, 149(1):120-126. [cited by applicant]
Fernandes et al. (Jan. 2016) “Type II and Type V Crispr Effector Nucleases From a Structural Biologist's Perspective”, Postepy Biochemical, 62(3):315-326. (Abstract). [cited by applicant]
Li et al. (2015) “Metabolic Engineering of [cited by applicant]
Orum et al. (Jun. 1, 2001) “Locked Nucleic Acids: A Promising Molecular Family for Gene-function Analysis and Antisense Drug Development”, Current Opinion in Molecular Therapeutics, 3(3):239-243. (Abstract). [cited by applicant]
Shelling et al. (May 1, 1994) “Targeted Integration of Transfected and Infected Adeno-Associated Virus Vectors Containing the Neomycin Resistance Gene”, Gene Therapy, 1(3):165-169 (Abstract). [cited by applicant]